| Authors | Clancy, R.L. Dunkley, M.L. Sockler, J. McDonald, C.F. |
|---|---|
| Type | Journal Article (Review) |
| Journal | Internal Medicine Journal 46(6): 684- 693 |
| PubMed ID | 27009822 |
| Year of Publication | 2016 |
| URL | http://www.ncbi.nlm.nih.gov/pubmed/27009822 |
| DOI | http://dx.doi.org/10.1186/10.1111/imj.13072 |
| Download |  Clancy_et_al-2016-Internal_Medicine_Journal.pdf (196.5 KB) |
| Abstract | BACKGROUND: Previous studies identified factors that modify response to an oral non-typeable Haemophilus influenzae (NTHi) vaccine in chronic obstructive pulmonary disease (COPD): severe COPD, moderate-severe exacerbations as end-point and a threshold prevalence of NTHi in the study population. More data are needed to confirm parameters that influence clinical outcomes. AIMS: The primary aim was to determine the efficacy of an oral NTHi vaccine (HI-164OV) in reducing the rate of exacerbations requiring systemic corticosteroids or hospitalisation in COPD. Secondary aims included effect on the proportion of patients experiencing such exacerbations, severity of infections and quality of life (St George Respiratory Questionnaire for COPD patients (SGRQ-C)). METHODS: This multi-centre, double-blind, placebo-controlled study was conducted at 21 Australian sites for 9 months in 2011. RESULTS: Three-hundred and twenty subjects with COPD, FEV1 <60% predicted and >/=1 moderate-severe exacerbations in the previous 12 months were recruited. The primary and secondary end-points for the intention-to-treat population aged 40-88 years were not achieved, and only 5% of subjects had an H. influenzae-positive sputum sample. Subsequent exploratory analysis of patients <65 years (91 subjects) indicated protection with respect to the primary and most of the secondary end-points, with SGRQ-C symptom scores lower at 3 and 6 months. CONCLUSION: Patients aged 40-88 years with moderate to severe COPD and low rates of H. influenzae-positive sputum were not protected against exacerbations by HI-1640V. Further studies are needed to confirm protection in subjects aged <65 years. Older age and low colonisation rates appear to affect adversely response to this vaccine. |
http://www.ibas.org.au/what-we-do/publications/3872821
Interstitial lung disease (ILD) is a chronic lung condition that causes stiff lungs and restricts sufferers from taking a deep breath. Exercise in a gym, or swimming, walking or riding a bike, can help...
SHIFT WORK AND BREASTFEEDING PROJECT
Researchers at Austin Health are looking for volunteers to participate in a study exploring the impact shift work has on breast milk composition. Participants will be compensated with a $100 gift voucher.
HEALTHY MALES AND FEMALES WANTED FOR SLEEP STUDY
Interested to participate in a study investigating the effect of fatigue on driving performance?
A/PROF MARK HOWARD AWARDED MAJOR COMPETITIVE MRFF GRANT
IBAS leads project to revolutionize Home Ventilation with $1.2 million grant for Assoc. Prof Mark Howard's research titled "Synchronise non-invasive ventilation at home".
PROF ANNE HOLLAND RECEIVES PRESTIGIOUS RESEARCH AWARD
Prof Anne Holland receives prestigious award for Excellent in Research Engagement and Impact from Monash University.
WORLD SLEEP DAY ON 17TH MARCH 2023
The benefits of quality sleep and to acknowledge the issue of sleep problems and their medical, educational, and social aspects as well as the prevention and management of sleep disorders, is promoted on World Sleep Day on the 17th March 2023.
A/PROF MARK HOWARD IS LISTED IN 'THE AUSTRALIAN'
The Australian's Research magazine names the top researcher and top research institution in each field of research, based on the number of citations for papers published in the top 20 journals in each field over the past five years.
© 2024 Institute for Breathing and Sleep. All Rights Reserved. ABN 39 093 685 879
Powered by Helmut Design | Manage
